Exosomal Non-coding RNAs: A New Approach to Melanoma Diagnosis and Therapeutic Strategy


Cite item

Full Text

Abstract

:Malignant melanoma (MM) is a highly aggressive cancer with a poor prognosis. Currently, although a variety of therapies are available for treating melanoma, MM is still a serious threat to the patient’s life due to numerous factors, such as the recurrence of tumors, the emergence of drug resistance, and the lack of effective therapeutic agents. Exosomes are biologically active lipid-bilayer extracellular vesicles secreted by diverse cell types that mediate intercellular signal communication. Studies found that exosomes are involved in cancer by carrying multiple bioactive molecules, including non-- coding RNAs (ncRNAs). The ncRNAs have been reported to play an important role in regulating proliferation, angiogenesis, immune regulation, invasion, metastasis, and treatment resistance of tumors. However, the functional role of exosomal ncRNAs in MM remains unknown. Therefore, this review summarizes the current state of melanoma diagnosis, treatment, and the application of exosomal ncRNAs in MM patients, which may provide new insights into the mechanisms involved in melanoma progression and serve as biomarkers for diagnosis and therapeutic targets.

About the authors

Jie Liu

Department of Dermatology, Skin Research Institute of Peking University Shenzhen Hospital, Peking University Shenzhen Hospital

Email: info@benthamscience.net

Xiaoping Hu

Department of Dermatology, Skin Research Institute of Peking University Shenzhen Hospital, Peking University Shenzhen Hospital

Email: info@benthamscience.net

Wenqiang Xin

Department of Neurology, University Medical Center Göttingen

Email: info@benthamscience.net

Xianbin Wang

Department of Emergency Medicine, The Second Affiliated Hospital of Baotou Medical College

Author for correspondence.
Email: info@benthamscience.net

References

  1. Karimkhani, C.; Green, A.C.; Nijsten, T.; Weinstock, M.A.; Dellavalle, R.P.; Naghavi, M.; Fitzmaurice, C. The global burden of melanoma: Results from the global burden of disease study 2015. Br. J. Dermatol., 2017, 177(1), 134-140. doi: 10.1111/bjd.15510 PMID: 28369739
  2. Conforti, C.; Zalaudek, I. Epidemiology and risk factors of melanoma: A review. Dermatol. Pract. Concept., 2021, 11(Suppl. 1), 2021161S. doi: 10.5826/dpc.11S1a161S PMID: 34447610
  3. Fonseca, A.; Xia, C.; Lorenzo, A.J.; Krailo, M.; Olson, T.A.; Pashankar, F.; Malogolowkin, M.H.; Amatruda, J.F.; Billmire, D.F.; Rodriguez-Galindo, C.; Frazier, A.L.; Shaikh, F. Detection of relapse by tumor markers versus imaging in children and adolescents with nongerminomatous malignant germ cell tumors: A report from the children’s oncology group. J. Clin. Oncol., 2019, 37(5), 396-402. doi: 10.1200/JCO.18.00790 PMID: 30576269
  4. Quinodoz, S.; Guttman, M. Long noncoding RNAs: An emerging link between gene regulation and nuclear organization. Trends Cell Biol., 2014, 24(11), 651-663. doi: 10.1016/j.tcb.2014.08.009 PMID: 25441720
  5. Wang, J.; Zhu, S.; Meng, N.; He, Y.; Lu, R.; Yan, G.R. ncRNA-encoded peptides or proteins and cancer. Mol. Ther., 2019, 27(10), 1718-1725. doi: 10.1016/j.ymthe.2019.09.001 PMID: 31526596
  6. Rebecca, V.W.; Sondak, V.K.; Smalley, K.S.M. A brief history of melanoma. Melanoma Res., 2012, 22(2), 114-122. doi: 10.1097/CMR.0b013e328351fa4d PMID: 22395415
  7. Saranga-Perry, V.; Ambe, C.; Zager, J.S.; Kudchadkar, R.R. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J. Clin., 2014, 64(3), 171-185. doi: 10.3322/caac.21224 PMID: 24676837
  8. Curtin, J.A.; Fridlyand, J.; Kageshita, T.; Patel, H.N.; Busam, K.J.; Kutzner, H.; Cho, K.H.; Aiba, S.; Bröcker, E.B.; LeBoit, P.E.; Pinkel, D.; Bastian, B.C. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med., 2005, 353(20), 2135-2147. doi: 10.1056/NEJMoa050092 PMID: 16291983
  9. Gandini, S.; Sera, F.; Cattaruzza, M.S.; Pasquini, P.; Picconi, O.; Boyle, P.; Melchi, C.F. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur. J. Cancer, 2005, 41(1), 45-60. doi: 10.1016/j.ejca.2004.10.016 PMID: 15617990
  10. Bataille, V.; Bykov, V.J.; Sasieni, P.; Harulow, S.; Cuzick, J.; Hemminki, K. Photoadaptation to ultraviolet (UV) radiation in vivo : Photoproducts in epidermal cells following UVB therapy for psoriasis. Br. J. Dermatol., 2000, 143(3), 477-483. doi: 10.1111/j.1365-2133.2000.03698.x PMID: 10971317
  11. Newton-Bishop, J.A.; Chang, Y.M.; Elliott, F.; Chan, M.; Leake, S.; Karpavicius, B.; Haynes, S.; Fitzgibbon, E.; Kukalizch, K.; Randerson-Moor, J.; Elder, D.E.; Bishop, D.T.; Barrett, J.H. Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. Eur. J. Cancer, 2011, 47(5), 732-741. doi: 10.1016/j.ejca.2010.10.008 PMID: 21084183
  12. Joshua, A.M. Melanoma prevention: Are we doing enough? A Canadian perspective. Curr. Oncol., 2012, 19(6), 462-467. doi: 10.3747/co.19.1222 PMID: 23300369
  13. Bevona, C.; Goggins, W.; Quinn, T.; Fullerton, J.; Tsao, H. Cutaneous melanomas associated with nevi. Arch. Dermatol., 2003, 139(12), 1620-1624. doi: 10.1001/archderm.139.12.1620 PMID: 14676081
  14. Holly, E.A.; Kelly, J.W.; Shpall, S.N.; Chiu, S.H. Number of melanocytic nevi as a major risk factor for malignant melanoma. J. Am. Acad. Dermatol., 1987, 17(3), 459-468. doi: 10.1016/S0190-9622(87)70230-8 PMID: 3655025
  15. Grob, J.J.; Gouvernet, J.; Aymar, D.; Mostaque, A.; Romano, M.H.; Collet, A.M.; Noe, M.C.; Diconstanzo, M.P.; Bonerandi, J.J. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer, 1990, 66(2), 387-395. doi: 10.1002/1097-0142(19900715)66:23.0.CO;2-J PMID: 2369719
  16. Halpern, A.C.; Guerry, D., IV; Elder, D.E.; Clark, W.H., Jr; Synnestvedt, M.; Norman, S.; Ayerle, R. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch. Dermatol., 1991, 127(7), 995-999. doi: 10.1001/archderm.1991.01680060069006 PMID: 2064418
  17. Ford, D.; Bliss, J.M.; Swerdlow, A.J.; Armstrong, B.K.; Franceschi, S.; Green, A.; Holly, E.A.; Mack, T.; Mackie, R.M.; Østerlind, A.; Walter, S.D.; Peto, J.; Easton, D.F. Risk of cutaneous melanoma associated with a family history of the disease. Int. J. Cancer, 1995, 62(4), 377-381. doi: 10.1002/ijc.2910620403 PMID: 7635561
  18. Hahn, A.W.; Menk, A.V.; Rivadeneira, D.B.; Augustin, R.C.; Xu, M.; Li, J.; Wu, X.; Mishra, A.K.; Gide, T.N.; Quek, C.; Zang, Y.; Spencer, C.N.; Menzies, A.M.; Daniel, C.R.; Hudgens, C.W.; Nowicki, T.; Haydu, L.E.; Khan, M.A.W.; Gopalakrishnan, V.; Burton, E.M.; Malke, J.; Simon, J.M.; Bernatchez, C.; Putluri, N.; Woodman, S.E.; Vashisht Gopal, Y.N.; Guerrieri, R.; Fischer, G.M.; Wang, J.; Wani, K.M.; Thompson, J.F.; Lee, J.E.; Hwu, P.; Ajami, N.; Gershenwald, J.E.; Long, G.V.; Scolyer, R.A.; Tetzlaff, M.T.; Lazar, A.J.; Schadendorf, D.; Wargo, J.A.; Kirkwood, J.M.; DeBerardinis, R.J.; Liang, H.; Futreal, A.; Zhang, J.; Wilmott, J.S.; Peng, W.; Davies, M.A.; Delgoffe, G.M.; Najjar, Y.G.; McQuade, J.L. Obesity is associated with altered tumor metabolism in metastatic melanoma. Clin. Cancer Res., 2023, 29(1), 154-164. doi: 10.1158/1078-0432.CCR-22-2661 PMID: 36166093
  19. Dobrică, E.C.; Banciu, M.L.; Kipkorir, V.; Khazeei Tabari, M.A.; Cox, M.J.; Simhachalam Kutikuppala, L.V.; Găman, M.A. Diabetes and skin cancers: Risk factors, molecular mechanisms and impact on prognosis. World J. Clin. Cases, 2022, 10(31), 11214-11225. doi: 10.12998/wjcc.v10.i31.11214 PMID: 36387789
  20. Rollan, M.P.; Cabrera, R.; Schwartz, R.A. Current knowledge of immunosuppression as a risk factor for skin cancer development. Crit. Rev. Oncol. Hematol., 2022, 177, 103754. doi: 10.1016/j.critrevonc.2022.103754 PMID: 35803453
  21. Asgari, M.M.; Warton, E.M.; Whittemore, A.S. Family history of skin cancer is associated with increased risk of cutaneous squamous cell carcinoma. Dermatol. Surg., 2015, 41(4), 481-486. doi: 10.1097/DSS.0000000000000292 PMID: 25760557
  22. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.C.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892), 949-954. doi: 10.1038/nature00766 PMID: 12068308
  23. Pratilas, C.A.; Taylor, B.S.; Ye, Q.; viale, A.; Sander, C.; Solit, D.B.; Rosen, N. V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA, 2009, 106(11), 4519-4524. doi: 10.1073/pnas.0900780106 PMID: 19251651
  24. Turski, M.L.; Vidwans, S.J.; Janku, F.; Garrido-Laguna, I.; Munoz, J.; Schwab, R.; Subbiah, V.; Rodon, J.; Kurzrock, R. Genomically driven tumors and actionability across histologies: BRAF -mutant cancers as a paradigm. Mol. Cancer Ther., 2016, 15(4), 533-547. doi: 10.1158/1535-7163.MCT-15-0643 PMID: 27009213
  25. Bauer, J.; Büttner, P.; Murali, R.; Okamoto, I.; Kolaitis, N.A.; Landi, M.T.; Scolyer, R.A.; Bastian, B.C. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res., 2011, 24(2), 345-351. doi: 10.1111/j.1755-148X.2011.00837.x PMID: 21324100
  26. Heppt, M.V.; Siepmann, T.; Engel, J.; Schubert-Fritschle, G.; Eckel, R.; Mirlach, L.; Kirchner, T.; Jung, A.; Gesierich, A.; Ruzicka, T.; Flaig, M.J.; Berking, C. Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care. BMC Cancer, 2017, 17(1), 536. doi: 10.1186/s12885-017-3529-5 PMID: 28797232
  27. Shtivelman, E.; Davies, M.A.; Hwu, P.; Yang, J.; Lotem, M.; Oren, M.; Flaherty, K.T.; Fisher, D.E. Pathways and therapeutic targets in melanoma. Oncotarget, 2014, 5(7), 1701-1752. doi: 10.18632/oncotarget.1892 PMID: 24743024
  28. He, J.; Huang, W.; Li, X.; Wang, J.; Nie, Y.; Li, G.; Wang, X.; Cao, H.; Chen, X.; Wang, X. A new ferroptosis-related genetic mutation risk model predicts the prognosis of skin cutaneous melanoma. Front. Genet., 2023, 13, 988909. doi: 10.3389/fgene.2022.988909 PMID: 36685905
  29. Smalley, K.S.M.; Xiao, M.; Villanueva, J.; Nguyen, T.K.; Flaherty, K.T.; Letrero, R.; Van Belle, P.; Elder, D.E.; Wang, Y.; Nathanson, K.L.; Herlyn, M. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene, 2009, 28(1), 85-94. doi: 10.1038/onc.2008.362 PMID: 18794803
  30. Wang, W.; Wang, S. The prognostic value of immune-related genes AZGP1, SLCO5A1, and CTF1 in Uveal melanoma. Front. Oncol., 2022, 12, 918230. doi: 10.3389/fonc.2022.918230 PMID: 36052234
  31. Prade, M.; Sancho-Garnier, H.; Cesarini, J.P.; Cochran, A. Difficulties encountered in the application of clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int. J. Cancer, 1980, 26(2), 159-163. doi: 10.1002/ijc.2910260206 PMID: 7009438
  32. Gerami, P.; Busam, K.; Cochran, A.; Cook, M.G.; Duncan, L.M.; Elder, D.E.; Fullen, D.R.; Guitart, J.; LeBoit, P.E.; Mihm, M.C., Jr; Prieto, V.G.; Rabkin, M.S.; Scolyer, R.A.; Xu, X.; Yun, S.J.; Obregon, R.; Yazdan, P.; Cooper, C.; Weitner, B.B.; Rademaker, A.; Barnhill, R.L. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am. J. Surg. Pathol., 2014, 38(7), 934-940. doi: 10.1097/PAS.0000000000000198 PMID: 24618612
  33. Davis, L.E.; Shalin, S.C.; Tackett, A.J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther., 2019, 20(11), 1366-1379. doi: 10.1080/15384047.2019.1640032 PMID: 31366280
  34. Kucher, C.; Zhang, P.J.; Pasha, T.; Elenitsas, R.; Wu, H.; Ming, M.E.; Elder, D.E.; Xu, X. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am. J. Dermatopathol., 2004, 26(6), 452-457. doi: 10.1097/00000372-200412000-00002 PMID: 15618925
  35. Willis, B.C.; Johnson, G.; Wang, J.; Cohen, C. SOX10: A useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl. Immunohistochem. Mol. Morphol., 2015, 23(2), 109-112. doi: 10.1097/PAI.0000000000000097 PMID: 25356946
  36. Nielsen, P.S.; Riber-Hansen, R.; Steiniche, T. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: Promising diagnostic tools in melanocytic lesions. Am. J. Dermatopathol., 2011, 33(4), 361-370. doi: 10.1097/DAD.0b013e3182120173 PMID: 21610457
  37. Biernacka, A.; Linos, K.D.; DeLong, P.A.; Suriawinata, A.A.; Padmanabhan, V.; Liu, X. A case of S-100 negative melanoma: A diagnostic pitfall in the workup of a poorly differentiated metastatic tumor of unknown origin. Cytojournal, 2016, 13, 21. doi: 10.4103/1742-6413.190914 PMID: 27729935
  38. Muzumdar, S.; Argraves, M.; Kristjansson, A.; Ferenczi, K.; Dadras, S.S. A quantitative comparison between SOX10 and MART-1 immunostaining to detect melanocytic hyperplasia in chronically sun-damaged skin. J. Cutan. Pathol., 2018, 45(4), 263-268. doi: 10.1111/cup.13115 PMID: 29377259
  39. Harpio, R.; Einarsson, R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem., 2004, 37(7), 512-518. doi: 10.1016/j.clinbiochem.2004.05.012 PMID: 15234232
  40. Desai, A.D.; Chinta, S.; Yeh, C.; Shah, V.P.; Shah, R.; Paskhover, B.; Schwartz, R.A. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: Prognostic capabilities and demographic variability. Arch. Dermatol. Res., 2022, 315(4), 799-806. doi: 10.1007/s00403-022-02425-0 PMID: 36318305
  41. Strojan, P. Role of radiotherapy in melanoma management. Radiol. Oncol., 2010, 44(1), 1-12. doi: 10.2478/v10019-010-0008-x PMID: 22933884
  42. Amaria, R.N.; Reddy, S.M.; Tawbi, H.A.; Davies, M.A.; Ross, M.I.; Glitza, I.C.; Cormier, J.N.; Lewis, C.; Hwu, W.J.; Hanna, E.; Diab, A.; Wong, M.K.; Royal, R.; Gross, N.; Weber, R.; Lai, S.Y.; Ehlers, R.; Blando, J.; Milton, D.R.; Woodman, S.; Kageyama, R.; Wells, D.K.; Hwu, P.; Patel, S.P.; Lucci, A.; Hessel, A.; Lee, J.E.; Gershenwald, J.; Simpson, L.; Burton, E.M.; Posada, L.; Haydu, L.; Wang, L.; Zhang, S.; Lazar, A.J.; Hudgens, C.W.; Gopalakrishnan, V.; Reuben, A.; Andrews, M.C.; Spencer, C.N.; Prieto, V.; Sharma, P.; Allison, J.; Tetzlaff, M.T.; Wargo, J.A. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med., 2018, 24(11), 1649-1654. doi: 10.1038/s41591-018-0197-1 PMID: 30297909
  43. Bhatia, S.; Tykodi, S.S.; Thompson, J.A. Treatment of metastatic melanoma: An overview. Oncology, 2009, 23(6), 488-496. PMID: 19544689
  44. Rooney, M.S.; Shukla, S.A.; Wu, C.J.; Getz, G.; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell, 2015, 160(1-2), 48-61. doi: 10.1016/j.cell.2014.12.033 PMID: 25594174
  45. Beermann, J.; Piccoli, M.T.; Viereck, J.; Thum, T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol. Rev., 2016, 96(4), 1297-1325. doi: 10.1152/physrev.00041.2015 PMID: 27535639
  46. Stachowiak, Z.; Narożna, B.; Szczepankiewicz, A. Non-Coding RNAs in pulmonary diseases: Comparison of different airway-derived biosamples. Int. J. Mol. Sci., 2023, 24(3), 2006. doi: 10.3390/ijms24032006 PMID: 36768329
  47. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5), 843-854. doi: 10.1016/0092-8674(93)90529-Y PMID: 8252621
  48. Vishnoi, A.; Rani, S. MiRNA biogenesis and regulation of diseases: An overview. Methods Mol. Biol., 2017, 1509, 1-10. doi: 10.1007/978-1-4939-6524-3_1 PMID: 27826912
  49. Carthew, R.W.; Sontheimer, E.J. Origins and mechanisms of miRNAs and siRNAs. Cell, 2009, 136(4), 642-655. doi: 10.1016/j.cell.2009.01.035 PMID: 19239886
  50. Bonasio, R.; Shiekhattar, R. Regulation of transcription by long noncoding RNAs. Annu. Rev. Genet., 2014, 48(1), 433-455. doi: 10.1146/annurev-genet-120213-092323 PMID: 25251851
  51. Okazaki, Y.; Furuno, M.; Kasukawa, T.; Adachi, J.; Bono, H.; Kondo, S.; Nikaido, I.; Osato, N.; Saito, R.; Suzuki, H.; Yamanaka, I.; Kiyosawa, H.; Yagi, K.; Tomaru, Y.; Hasegawa, Y.; Nogami, A.; Schönbach, C.; Gojobori, T.; Baldarelli, R.; Hill, D.P.; Bult, C.; Hume, D.A.; Quackenbush, J.; Schriml, L.M.; Kanapin, A.; Matsuda, H.; Batalov, S.; Beisel, K.W.; Blake, J.A.; Bradt, D.; Brusic, V.; Chothia, C.; Corbani, L.E.; Cousins, S.; Dalla, E.; Dragani, T.A.; Fletcher, C.F.; Forrest, A.; Frazer, K.S.; Gaasterland, T.; Gariboldi, M.; Gissi, C.; Godzik, A.; Gough, J.; Grimmond, S.; Gustincich, S.; Hirokawa, N.; Jackson, I.J.; Jarvis, E.D.; Kanai, A.; Kawaji, H.; Kawasawa, Y.; Kedzierski, R.M.; King, B.L.; Konagaya, A.; Kurochkin, I.V.; Lee, Y.; Lenhard, B.; Lyons, P.A.; Maglott, D.R.; Maltais, L.; Marchionni, L.; McKenzie, L.; Miki, H.; Nagashima, T.; Numata, K.; Okido, T.; Pavan, W.J.; Pertea, G.; Pesole, G.; Petrovsky, N.; Pillai, R.; Pontius, J.U.; Qi, D.; Ramachandran, S.; Ravasi, T.; Reed, J.C.; Reed, D.J.; Reid, J.; Ring, B.Z.; Ringwald, M.; Sandelin, A.; Schneider, C.; Semple, C.A.; Setou, M.; Shimada, K.; Sultana, R.; Takenaka, Y.; Taylor, M.S.; Teasdale, R.D.; Tomita, M.; Verardo, R.; Wagner, L.; Wahlestedt, C.; Wang, Y.; Watanabe, Y.; Wells, C.; Wilming, L.G.; Wynshaw-Boris, A.; Yanagisawa, M.; Yang, I.; Yang, L.; Yuan, Z.; Zavolan, M.; Zhu, Y.; Zimmer, A.; Carninci, P.; Hayatsu, N.; Hirozane-Kishikawa, T.; Konno, H.; Nakamura, M.; Sakazume, N.; Sato, K.; Shiraki, T.; Waki, K.; Kawai, J.; Aizawa, K.; Arakawa, T.; Fukuda, S.; Hara, A.; Hashizume, W.; Imotani, K.; Ishii, Y.; Itoh, M.; Kagawa, I.; Miyazaki, A.; Sakai, K.; Sasaki, D.; Shibata, K.; Shinagawa, A.; Yasunishi, A.; Yoshino, M.; Waterston, R.; Lander, E.S.; Rogers, J.; Birney, E.; Hayashizaki, Y.; Consortium, F. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature, 2002, 420(6915), 563-573. doi: 10.1038/nature01266 PMID: 12466851
  52. Ponting, C.P.; Oliver, P.L.; Reik, W. Evolution and functions of long noncoding RNAs. Cell, 2009, 136(4), 629-641. doi: 10.1016/j.cell.2009.02.006 PMID: 19239885
  53. Wierzbicki, A.T.; Haag, J.R.; Pikaard, C.S. Noncoding transcription by RNA polymerase Pol IVb/Pol V mediates transcriptional silencing of overlapping and adjacent genes. Cell, 2008, 135(4), 635-648. doi: 10.1016/j.cell.2008.09.035 PMID: 19013275
  54. Wierzbicki, A.T.; Ream, T.S.; Haag, J.R.; Pikaard, C.S. RNA polymerase V transcription guides ARGONAUTE4 to chromatin. Nat. Genet., 2009, 41(5), 630-634. doi: 10.1038/ng.365 PMID: 19377477
  55. McKinlay, A.; Podicheti, R.; Wendte, J.M.; Cocklin, R.; Rusch, D.B. RNA polymerases IV and V influence the 3′ boundaries of Polymerase II transcription units in Arabidopsis. RNA Biol., 2018, 15(2), 269-279. doi: 10.1080/15476286.2017.1409930 PMID: 29199514
  56. Memczak, S.; Jens, M.; Elefsinioti, A.; Torti, F.; Krueger, J.; Rybak, A.; Maier, L.; Mackowiak, S.D.; Gregersen, L.H.; Munschauer, M.; Loewer, A.; Ziebold, U.; Landthaler, M.; Kocks, C.; le Noble, F.; Rajewsky, N. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature, 2013, 495(7441), 333-338. doi: 10.1038/nature11928 PMID: 23446348
  57. Abu, N.; Jamal, R. Circular RNAs as promising biomarkers: A mini-review. Front. Physiol., 2016, 7, 355. doi: 10.3389/fphys.2016.00355 PMID: 27588005
  58. Li, R.; Jiang, J.; Shi, H.; Qian, H.; Zhang, X.; Xu, W. CircRNA: A rising star in gastric cancer. Cell. Mol. Life Sci., 2020, 77(9), 1661-1680. doi: 10.1007/s00018-019-03345-5 PMID: 31659415
  59. Dong, Y.; He, D.; Peng, Z.; Peng, W.; Shi, W.; Wang, J.; Li, B.; Zhang, C.; Duan, C. Circular RNAs in cancer: An emerging key player. J. Hematol. Oncol., 2017, 10(1), 2. doi: 10.1186/s13045-016-0370-2 PMID: 28049499
  60. Tan, S.; Gou, Q.; Pu, W.; Guo, C.; Yang, Y.; Wu, K.; Liu, Y.; Liu, L.; Wei, Y.Q.; Peng, Y. Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. Cell Res., 2018, 28(6), 693-695. doi: 10.1038/s41422-018-0033-7 PMID: 29628502
  61. Herranz, H.; Cohen, S.M. MicroRNAs and gene regulatory networks: Managing the impact of noise in biological systems. Genes Dev., 2010, 24(13), 1339-1344. doi: 10.1101/gad.1937010 PMID: 20595229
  62. Providing a comprehensive district psychiatric service for the adult mentally ill. Appendix 1. Syndicate ‘A’ discussion paper. Rep. Health Soc. Subj., 1974, (8), 15-17. PMID: 4463426
  63. Guarnerio, J.; Bezzi, M.; Jeong, J.C.; Paffenholz, S.V.; Berry, K.; Naldini, M.M.; Lo-Coco, F.; Tay, Y.; Beck, A.H.; Pandolfi, P.P. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell, 2016, 166(4), 1055-1056. doi: 10.1016/j.cell.2016.07.035 PMID: 27518567
  64. Xu, R.; Greening, D.W.; Rai, A.; Ji, H.; Simpson, R.J. Highly-purified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and functionally distinct. Methods, 2015, 87, 11-25. doi: 10.1016/j.ymeth.2015.04.008 PMID: 25890246
  65. Livshits, M.A.; Khomyakova, E.; Evtushenko, E.G.; Lazarev, V.N.; Kulemin, N.A.; Semina, S.E.; Generozov, E.V.; Govorun, V.M. Isolation of exosomes by differential centrifugation: Theoretical analysis of a commonly used protocol. Sci. Rep., 2015, 5(1), 17319. doi: 10.1038/srep17319 PMID: 26616523
  66. Shu, S.L.; Allen, C.L.; Benjamin-Davalos, S.; Koroleva, M.; MacFarland, D.; Minderman, H.; Ernstoff, M.S. A Rapid Exosome Isolation Using Ultrafiltration and Size Exclusion Chromatography (REIUS) method for exosome isolation from melanoma cell lines. Methods Mol. Biol., 2021, 2265, 289-304. doi: 10.1007/978-1-0716-1205-7_22 PMID: 33704723
  67. Van Deun, J.; Jo, A.; Li, H.; Lin, H.Y.; Weissleder, R.; Im, H.; Lee, H. Integrated dual-mode chromatography to enrich extracellular vesicles from plasma. Adv. Biosyst., 2020, 4(12), 1900310. doi: 10.1002/adbi.201900310 PMID: 32351054
  68. Mizutani, K.; Terazawa, R.; Kameyama, K.; Kato, T.; Horie, K.; Tsuchiya, T.; Seike, K.; Ehara, H.; Fujita, Y.; Kawakami, K.; Ito, M.; Deguchi, T. Isolation of prostate cancer-related exosomes. Anticancer Res., 2014, 34(7), 3419-3423. PMID: 24982349
  69. Ding, M.; Wang, C.; Lu, X.; Zhang, C.; Zhou, Z.; Chen, X.; Zhang, C.Y.; Zen, K.; Zhang, C. Comparison of commercial exosome isolation kits for circulating exosomal microRNA profiling. Anal. Bioanal. Chem., 2018, 410(16), 3805-3814. doi: 10.1007/s00216-018-1052-4 PMID: 29671027
  70. Guo, S.C.; Tao, S.C.; Dawn, H. Microfluidics-based on-a-chip systems for isolating and analysing extracellular vesicles. J. Extracell. Vesicles, 2018, 7(1), 1508271. doi: 10.1080/20013078.2018.1508271 PMID: 30151077
  71. Gao, Z.; Pang, B.; Li, J.; Gao, N.; Fan, T.; Li, Y. Emerging role of exosomes in liquid biopsy for monitoring prostate cancer invasion and metastasis. Front. Cell Dev. Biol., 2021, 9, 679527. doi: 10.3389/fcell.2021.679527 PMID: 34017837
  72. Thery, C.; Amigorena, S.; Raposo, G.; Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell. Biol., 2006, Chapter 3, 22. doi: 10.1002/0471143030.cb0322s30
  73. Li, Y.; Zhang, Z.; Chen, J.; Liu, W.; Lai, W.; Liu, B.; Li, X.; Liu, L.; Xu, S.; Dong, Q.; Wang, M.; Duan, X.; Tan, J.; Zheng, Y.; Zhang, P.; Fan, G.; Wong, J.; Xu, G.L.; Wang, Z.; Wang, H.; Gao, S.; Zhu, B. Stella safeguards the oocyte methylome by preventing de novo methylation mediated by DNMT1. Nature, 2018, 564(7734), 136-140. doi: 10.1038/s41586-018-0751-5 PMID: 30487604
  74. Arraud, N.; Linares, R.; Tan, S.; Gounou, C.; Pasquet, J.M.; Mornet, S.; Brisson, A.R. Extracellular vesicles from blood plasma: Determination of their morphology, size, phenotype and concentration. J. Thromb. Haemost., 2014, 12(5), 614-627. doi: 10.1111/jth.12554 PMID: 24618123
  75. Kashkanova, A.D.; Blessing, M.; Gemeinhardt, A.; Soulat, D.; Sandoghdar, V. Precision size and refractive index analysis of weakly scattering nanoparticles in polydispersions. Nat. Methods, 2022, 19(5), 586-593. doi: 10.1038/s41592-022-01460-z PMID: 35534632
  76. Inglis, H.; Norris, P.; Danesh, A. Techniques for the analysis of extracellular vesicles using flow cytometry. J. Vis. Exp., 2015, 97
  77. Tiruvayipati, S.; Wolfgeher, D.; Yue, M.; Duan, F.; Andrade, J.; Jiang, H.; Schuger, L. Variability in protein cargo detection in technical and biological replicates of exosome-enriched extracellular vesicles. PLoS One, 2020, 15(3), e0228871. doi: 10.1371/journal.pone.0228871 PMID: 32119684
  78. Skliar, M.; Chernyshev, V.S. Imaging of extracellular vesicles by atomic force microscopy. J. Vis. Exp., 2019, 151
  79. Sung, B.H.; von Lersner, A.; Guerrero, J.; Krystofiak, E.S.; Inman, D.; Pelletier, R.; Zijlstra, A.; Ponik, S.M.; Weaver, A.M. A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells. Nat. Commun., 2020, 11(1), 2092. doi: 10.1038/s41467-020-15747-2 PMID: 32350252
  80. Di Leva, G.; Piovan, C.; Gasparini, P.; Ngankeu, A.; Taccioli, C.; Briskin, D.; Cheung, D.G.; Bolon, B.; Anderlucci, L.; Alder, H.; Nuovo, G.; Li, M.; Iorio, M.V.; Galasso, M.; Ramasamy, S.; Marcucci, G.; Perrotti, D.; Powell, K.A.; Bratasz, A.; Garofalo, M.; Nephew, K.P.; Croce, C.M. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet., 2013, 9(3), e1003311. doi: 10.1371/journal.pgen.1003311 PMID: 23505378
  81. Felicetti, F.; De Feo, A.; Coscia, C.; Puglisi, R.; Pedini, F.; Pasquini, L.; Bellenghi, M.; Errico, M.C.; Pagani, E.; Carè, A. Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J. Transl. Med., 2016, 14(1), 56. doi: 10.1186/s12967-016-0811-2 PMID: 26912358
  82. Que, R.; Lin, C.; Ding, G.; Wu, Z.; Cao, L. Increasing the immune activity of exosomes: The effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pancreatic cancer. J. Zhejiang Univ. Sci. B, 2016, 17(5), 352-360. doi: 10.1631/jzus.B1500305 PMID: 27143262
  83. Fabbri, M.; Paone, A.; Calore, F.; Galli, R.; Gaudio, E.; Santhanam, R.; Lovat, F.; Fadda, P.; Mao, C.; Nuovo, G.J.; Zanesi, N.; Crawford, M.; Ozer, G.H.; Wernicke, D.; Alder, H.; Caligiuri, M.A.; Nana-Sinkam, P.; Perrotti, D.; Croce, C.M. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci., 2012, 109(31), E2110-E2116. doi: 10.1073/pnas.1209414109 PMID: 22753494
  84. Li, X.; Liu, D.; Chen, H.; Zeng, B.; Zhao, Q.; Zhang, Y.; Chen, Y.; Wang, J.; Xing, H.R. Melanoma stem cells promote metastasis via exosomal miR-1268a inactivation of autophagy. Biol. Res., 2022, 55(1), 29. doi: 10.1186/s40659-022-00397-z PMID: 36182945
  85. Sun, X.; Li, J.; Sun, Y.; Zhang, Y.; Dong, L.; Shen, C.; Yang, L.; Yang, M.; Li, Y.; Shen, G.; Tu, Y.; Tao, J. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget, 2016, 7(33), 53558-53570. doi: 10.18632/oncotarget.10669 PMID: 27448964
  86. Ma, Y.; Wang, N.; Yang, S. Skin cutaneous melanoma properties of immune-related lncRNAs identifying potential prognostic biomarkers. Aging, 2022, 14(7), 3030-3048. doi: 10.18632/aging.203982 PMID: 35361740
  87. Chen, L.; Ma, D.; Li, Y.; Li, X.; Zhao, L.; Zhang, J.; Song, Y. Effect of long non-coding RNA PVT1 on cell proliferation and migration in melanoma. Int. J. Mol. Med., 2018, 41(3), 1275-1282. PMID: 29286144
  88. Luan, W.; Li, R.; Liu, L.; Ni, X.; Shi, Y.; Xia, Y.; Wang, J.; Lu, F.; Xu, B. Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p. Oncotarget, 2017, 8(49), 85401-85414. doi: 10.18632/oncotarget.19910 PMID: 29156728
  89. Wu, L.; Zhu, L.; Li, Y.; Zheng, Z.; Lin, X.; Yang, C. LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis. Cancer Cell Int., 2020, 20(1), 12. doi: 10.1186/s12935-019-1087-4 PMID: 31938020
  90. Zhu, L.; Wang, Y.; Yang, C.; Li, Y.; Zheng, Z.; Wu, L.; Zhou, H. RETRACTED ARTICLE: Long non-coding RNA MIAT promotes the growth of melanoma via targeting miR-150. Hum. Cell, 2020, 33(3), 819-829. doi: 10.1007/s13577-020-00340-y PMID: 32300960
  91. Tuo, B.; Chen, Z.; Dang, Q.; Chen, C.; Zhang, H.; Hu, S.; Sun, Z. Roles of exosomal circRNAs in tumour immunity and cancer progression. Cell Death Dis., 2022, 13(6), 539. doi: 10.1038/s41419-022-04949-9 PMID: 35676257
  92. Yanagisawa, S.; Baker, J.R.; Vuppusetty, C.; Fenwick, P.; Donnelly, L.E.; Ito, K.; Barnes, P.J. Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. Am. J. Physiol. Lung Cell. Mol. Physiol., 2017, 313(2), L230-L239. doi: 10.1152/ajplung.00382.2016 PMID: 28522564
  93. Wang, J.; Zhao, X.; Wang, Y.; Ren, F.; Sun, D.; Yan, Y.; Kong, X.; Bu, J.; Liu, M.; Xu, S. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. Cell Death Dis., 2020, 11(1), 32. doi: 10.1038/s41419-020-2230-9 PMID: 31949130
  94. Díaz-Lagares, A.; Alegre, E.; Arroyo, A.; González-Cao, M.; Zudaire, M.E.; Viteri, S.; Martín-Algarra, S.; González, A. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol., 2011, 32(6), 1155-1161. doi: 10.1007/s13277-011-0218-x PMID: 21858537
  95. Alegre, E.; Sammamed, M.; Fernández-Landázuri, S.; Zubiri, L.; González, Á. Circulating biomarkers in malignant melanoma. Adv. Clin. Chem., 2015, 69, 47-89. doi: 10.1016/bs.acc.2014.12.002 PMID: 25934359
  96. Egberts, F.; Hitschler, W.N.; Weichenthal, M.; Hauschild, A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: Lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res., 2009, 19(1), 31-35. doi: 10.1097/CMR.0b013e32831993cc PMID: 19104452
  97. Wevers, K.P.; Kruijff, S.; Speijers, M.J.; Bastiaannet, E.; Muller Kobold, A.C.; Hoekstra, H.J. S-100B: A stronger prognostic biomarker than LDH in stage IIIB-C melanoma. Ann. Surg. Oncol., 2013, 20(8), 2772-2779. doi: 10.1245/s10434-013-2949-y PMID: 23512078
  98. Kucharzewska, P.; Belting, M. Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J. Extracell. Vesicles, 2013, 2(1), 20304. doi: 10.3402/jev.v2i0.20304 PMID: 24009895
  99. Wendler, F.; Bota-Rabassedas, N.; Franch-Marro, X. Cancer becomes wasteful: Emerging roles of exosomes † in cell-fate determination. J. Extracell. Vesicles, 2013, 2(1), 22390. doi: 10.3402/jev.v2i0.22390 PMID: 24223259
  100. Wang, Z.; Chen, J.Q.; Liu, J.; Tian, L. Exosomes in tumor microenvironment: Novel transporters and biomarkers. J. Transl. Med., 2016, 14(1), 297. doi: 10.1186/s12967-016-1056-9 PMID: 27756426
  101. Teng, Y.; Ren, Y.; Hu, X.; Mu, J.; Samykutty, A.; Zhuang, X.; Deng, Z.; Kumar, A.; Zhang, L.; Merchant, M.L.; Yan, J.; Miller, D.M.; Zhang, H.G. MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat. Commun., 2017, 8(1), 14448. doi: 10.1038/ncomms14448 PMID: 28211508
  102. Li, Y.; Yin, Z.; Fan, J.; Zhang, S.; Yang, W. The roles of exosomal miRNAs and lncRNAs in lung diseases. Signal Transduct. Target. Ther., 2019, 4(1), 47. doi: 10.1038/s41392-019-0080-7 PMID: 31728212
  103. Desmond, B.J.; Dennett, E.R.; Danielson, K.M. Circulating extracellular vesicle MicroRNA as diagnostic biomarkers in early colorectal cancer-A review. Cancers, 2019, 12(1), 52. doi: 10.3390/cancers12010052 PMID: 31878015
  104. Kumata, Y.; Iinuma, H.; Suzuki, Y.; Tsukahara, D.; Midorikawa, H.; Igarashi, Y.; Soeda, N.; Kiyokawa, T.; Horikawa, M.; Fukushima, R. Exosome-encapsulated microRNA-23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage. Oncol. Rep., 2018, 40(1), 319-330. doi: 10.3892/or.2018.6418 PMID: 29749537
  105. Tengda, L.; Shuping, L.; Mingli, G.; Jie, G.; Yun, L.; Weiwei, Z.; Anmei, D. Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res., 2018, 28(4), 295-303. doi: 10.1097/CMR.0000000000000450 PMID: 29750752
  106. Lunavat, T.R.; Cheng, L.; Einarsdottir, B.O.; Olofsson Bagge, R.; Veppil Muralidharan, S.; Sharples, R.A.; Lässer, C.; Gho, Y.S.; Hill, A.F.; Nilsson, J.A.; Lötvall, J. BRAF V600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. Proc. Natl. Acad. Sci. USA, 2017, 114(29), E5930-E5939. doi: 10.1073/pnas.1705206114 PMID: 28684402
  107. Chen, L.; Karisma, V.W.; Liu, H.; Zhong, L. MicroRNA-300: A transcellular mediator in exosome regulates melanoma progression. Front. Oncol., 2019, 9, 1005. doi: 10.3389/fonc.2019.01005 PMID: 31681565
  108. Zhuang, G.; Wu, X.; Jiang, Z.; Kasman, I.; Yao, J.; Guan, Y.; Oeh, J.; Modrusan, Z.; Bais, C.; Sampath, D.; Ferrara, N. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J., 2012, 31(17), 3513-3523. doi: 10.1038/emboj.2012.183 PMID: 22773185
  109. Flockhart, R.J.; Webster, D.E.; Qu, K.; Mascarenhas, N.; Kovalski, J.; Kretz, M.; Khavari, P.A. BRAF V600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res., 2012, 22(6), 1006-1014. doi: 10.1101/gr.140061.112 PMID: 22581800
  110. Li, R.; Zhang, L.; Jia, L.; Duan, Y.; Li, Y.; Bao, L.; Sha, N. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS One, 2014, 9(6), e100893. doi: 10.1371/journal.pone.0100893 PMID: 24967732
  111. Khaitan, D.; Dinger, M.E.; Mazar, J.; Crawford, J.; Smith, M.A.; Mattick, J.S.; Perera, R.J. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res., 2011, 71(11), 3852-3862. doi: 10.1158/0008-5472.CAN-10-4460 PMID: 21558391
  112. Huang, S.; Lyu, S.; Gao, Z.; Zha, W.; Wang, P.; Shan, Y.; He, J.; Li, Y. m6A-Related lncRNAs are potential biomarkers for the prognosis of metastatic skin cutaneous melanoma. Front. Mol. Biosci., 2021, 8, 687760. doi: 10.3389/fmolb.2021.687760 PMID: 34026852
  113. Gezer, U.; Özgür, E.; Cetinkaya, M.; Isin, M.; Dalay, N. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol. Int., 2014, 38(9), n/a. doi: 10.1002/cbin.10301 PMID: 24798520
  114. Wang, J.; Zhou, Y.; Lu, J.; Sun, Y.; Xiao, H.; Liu, M.; Tian, L. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med. Oncol., 2014, 31(9), 148. doi: 10.1007/s12032-014-0148-8 PMID: 25099764
  115. Wu, C.F.; Tan, G.H.; Ma, C.C.; Li, L. The non-coding RNA llme23 drives the malignant property of human melanoma cells. J. Genet. Genomics, 2013, 40(4), 179-188. doi: 10.1016/j.jgg.2013.03.001 PMID: 23618401
  116. Lessard, L.; Liu, M.; Marzese, D.M.; Wang, H.; Chong, K.; Kawas, N.; Donovan, N.C.; Kiyohara, E.; Hsu, S.; Nelson, N.; Izraely, S.; Sagi-Assif, O.; Witz, I.P.; Ma, X.J.; Luo, Y.; Hoon, D.S.B. The CASC15 long intergenic noncoding RNA locus is involved in melanoma progression and phenotype switching. J. Invest. Dermatol., 2015, 135(10), 2464-2474. doi: 10.1038/jid.2015.200 PMID: 26016895
  117. Wang, S.; Zhang, K.; Tan, S.; Xin, J.; Yuan, Q.; Xu, H.; Xu, X.; Liang, Q.; Christiani, D.C.; Wang, M.; Liu, L.; Du, M. Circular RNAs in body fluids as cancer biomarkers: The new frontier of liquid biopsies. Mol. Cancer, 2021, 20(1), 13. doi: 10.1186/s12943-020-01298-z PMID: 33430880
  118. Wang, H.; Tang, Z.; Duan, J.; Zhou, C.; Xu, K.; Mu, H. Cancer-released exosomal circular RNA circ_0008717 promotes cell tumorigenicity through microRNA-1287-5p/P21-activated kinase 2 (PAK2) axis in non-small cell lung cancer. Bioengineered, 2022, 13(4), 8937-8949. doi: 10.1080/21655979.2022.2056822 PMID: 35333693
  119. Zheng, P.; Gao, H.; Xie, X.; Lu, P. Plasma exosomal hsa_circ_0015286 as a potential diagnostic and prognostic biomarker for gastric cancer. Pathol. Oncol. Res., 2022, 28, 1610446. doi: 10.3389/pore.2022.1610446 PMID: 35755416
  120. Hong, L.; Xu, L.; Jin, L.; Xu, K.; Tang, W.; Zhu, Y.; Qiu, X.; Wang, J. Exosomal circular RNA hsa_circ_0006220, and hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic cancer. J. Clin. Lab. Anal., 2022, 36(6), e24447. doi: 10.1002/jcla.24447 PMID: 35446993
  121. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782. doi: 10.1038/nrd2614 PMID: 18758474
  122. Pan, J.; Ruan, W.; Qin, M.; Long, Y.; Wan, T.; Yu, K.; Zhai, Y.; Wu, C.; Xu, Y. Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles. Sci. Rep., 2018, 8(1), 1117. doi: 10.1038/s41598-018-19463-2 PMID: 29348670
  123. Zhang, X.; Cai, A.; Gao, Y.; Zhang, Y.; Duan, X.; Men, K. Treatment of melanoma by nano-conjugate-delivered wee1 siRNA. Mol. Pharm., 2021, 18(9), 3387-3400. doi: 10.1021/acs.molpharmaceut.1c00316 PMID: 34375118
  124. Stremersch, S.; Vandenbroucke, R.E.; Van Wonterghem, E.; Hendrix, A.; De Smedt, S.C.; Raemdonck, K. Comparing exosome-like vesicles with liposomes for the functional cellular delivery of small RNAs. J. Control. Release, 2016, 232, 51-61. doi: 10.1016/j.jconrel.2016.04.005 PMID: 27072025
  125. Wang, Z.; Song, L.; Liu, Q.; Tian, R.; Shang, Y.; Liu, F.; Liu, S.; Zhao, S.; Han, Z.; Sun, J.; Jiang, Q.; Ding, B. A tubular DNA nanodevice as a siRNA/chemo-drug co-delivery vehicle for combined cancer therapy. Angew. Chem. Int. Ed., 2021, 60(5), 2594-2598. doi: 10.1002/anie.202009842 PMID: 33089613
  126. Thyagarajan, A.; Shaban, A.; Sahu, R.P. MicroRNA-directed cancer therapies: Implications in melanoma intervention. J. Pharmacol. Exp. Ther., 2018, 364(1), 1-12. doi: 10.1124/jpet.117.242636 PMID: 29054858
  127. Fattore, L.; Costantini, S.; Malpicci, D.; Ruggiero, C.F.; Ascierto, P.A.; Croce, C.M.; Mancini, R.; Ciliberto, G. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget, 2017, 8(13), 22262-22278. doi: 10.18632/oncotarget.14763 PMID: 28118616
  128. Ryu, B.; Hwang, S.; Alani, R.M. MicroRNAs as an emerging target for melanoma therapy. J. Invest. Dermatol., 2013, 133(5), 1137-1139. doi: 10.1038/jid.2012.505 PMID: 23594536
  129. Jiang, L.; Lv, X.; Li, J.; Li, J.; Li, X.; Li, W.; Li, Y. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochem., 2012, 114(6), 582-588. doi: 10.1016/j.acthis.2011.11.001 PMID: 22130252
  130. Mishra, P.J.; Mishra, P.J.; Merlino, G. Integrated genomics identifies miR-32/MCL-1 pathway as a critical driver of melanomagenesis: Implications for miR-replacement and combination therapy. PLoS One, 2016, 11(11), e0165102. doi: 10.1371/journal.pone.0165102 PMID: 27846237
  131. Ling, H.; Fabbri, M.; Calin, G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov., 2013, 12(11), 847-865. doi: 10.1038/nrd4140 PMID: 24172333
  132. Winkle, M.; El-Daly, S.M.; Fabbri, M.; Calin, G.A. Noncoding RNA therapeutics - challenges and potential solutions. Nat. Rev. Drug Discov., 2021, 20(8), 629-651. doi: 10.1038/s41573-021-00219-z PMID: 34145432
  133. Arun, G.; Diermeier, S.D.; Spector, D.L. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol. Med., 2018, 24(3), 257-277. doi: 10.1016/j.molmed.2018.01.001 PMID: 29449148
  134. Qu, S.; Jiao, Z.; Lu, G.; Yao, B.; Wang, T.; Rong, W.; Xu, J.; Fan, T.; Sun, X.; Yang, R.; Wang, J.; Yao, Y.; Xu, G.; Yan, X.; Wang, T.; Liang, H.; Zen, K. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol., 2021, 22(1), 104. doi: 10.1186/s13059-021-02331-0 PMID: 33849634
  135. Shi, L.; Yang, Y.; Li, M.; Li, C.; Zhou, Z.; Tang, G.; Wu, L.; Yao, Y.; Shen, X.; Hou, Z.; Jia, H. LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis. Mol. Ther., 2022, 30(4), 1564-1577. doi: 10.1016/j.ymthe.2022.01.003 PMID: 35051616
  136. Charpentier, M.; Dupré, E.; Fortun, A.; Briand, F.; Maillasson, M.; Com, E.; Pineau, C.; Labarrière, N.; Rabu, C.; Lang, F. hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cells. Mol. Oncol., 2022, 16(3), 594-606. doi: 10.1002/1878-0261.13088 PMID: 34418284
  137. Dai, S.; Wei, D.; Wu, Z.; Zhou, X.; Wei, X.; Huang, H.; Li, G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther., 2008, 16(4), 782-790. doi: 10.1038/mt.2008.1 PMID: 18362931
  138. Xu, S.; Wang, H.; Pan, H.; Shi, Y.; Li, T.; Ge, S.; Jia, R.; Zhang, H.; Fan, X. ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma. Cancer Lett., 2016, 381(1), 41-48. doi: 10.1016/j.canlet.2016.07.024 PMID: 27461581
  139. Luan, W.; Li, L.; Shi, Y.; Bu, X.; Xia, Y.; Wang, J.; Djangmah, H.S.; Liu, X.; You, Y.; Xu, B. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget, 2016, 7(39), 63901-63912. doi: 10.18632/oncotarget.11564 PMID: 27564100
  140. Tang, L.; Zhang, W.; Su, B.; Yu, B. Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. BioMed Res. Int., 2013, 2013, 1-7. doi: 10.1155/2013/251098 PMID: 23862139
  141. Lin, Q.; Jiang, H.; Lin, D.; Circular, R.N.A. Circular RNA ITCH downregulates GLUT1 and suppresses glucose uptake in melanoma to inhibit cancer cell proliferation. J. Dermatolog. Treat., 2021, 32(2), 231-235. doi: 10.1080/09546634.2019.1654069 PMID: 31403357
  142. Zhang, L.; Li, Y.; Liu, W.; Li, H.; Zhu, Z. Analysis of the complex interaction of CDR1as-miRNA-protein and detection of its novel role in melanoma. Oncol. Lett., 2018, 16(1), 1219-1225. doi: 10.3892/ol.2018.8700 PMID: 29963195
  143. Ray, A.; Kunhiraman, H.; Perera, R.J. The paradoxical behavior of microRNA-211 in melanomas and other human cancers. Front. Oncol., 2021, 10, 628367. doi: 10.3389/fonc.2020.628367 PMID: 33628737
  144. Tang, H.; Ma, M.; Dai, J.; Cui, C.; Si, L.; Sheng, X.; Chi, Z.; Xu, L.; Yu, S.; Xu, T.; Yan, J.; Yu, H.; Yang, L.; Kong, Y.; Guo, J. miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy. J. Exp. Clin. Cancer Res., 2019, 38(1), 212. doi: 10.1186/s13046-019-1190-3 PMID: 31118065
  145. Melnik, B.C. MiR-21: An environmental driver of malignant melanoma? J. Transl. Med., 2015, 13(1), 202. doi: 10.1186/s12967-015-0570-5 PMID: 26116372
  146. Han, Y.; Fang, J.; Xiao, Z.; Deng, J.; Zhang, M.; Gu, L. Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling. J. Cancer Res. Clin. Oncol., 2021, 147(3), 767-777. doi: 10.1007/s00432-020-03484-4 PMID: 33389075
  147. Leucci, E.; Vendramin, R.; Spinazzi, M.; Laurette, P.; Fiers, M.; Wouters, J.; Radaelli, E.; Eyckerman, S.; Leonelli, C.; Vanderheyden, K.; Rogiers, A.; Hermans, E.; Baatsen, P.; Aerts, S.; Amant, F.; Van Aelst, S.; van den Oord, J.; de Strooper, B.; Davidson, I.; Lafontaine, D.L.J.; Gevaert, K.; Vandesompele, J.; Mestdagh, P.; Marine, J.C. Melanoma addiction to the long non-coding RNA SAMMSON. Nature, 2016, 531(7595), 518-522. doi: 10.1038/nature17161 PMID: 27008969
  148. Han, S.; Yan, Y.; Ren, Y.; Hu, Y.; Wang, Y.; Chen, L.; Zhi, Z.; Zheng, Y.; Shao, Y.; Liu, J. LncRNA SAMMSON mediates adaptive resistance to RAF inhibition in braf-mutant melanoma cells. Cancer Res., 2021, 81(11), 2918-2929. doi: 10.1158/0008-5472.CAN-20-3145 PMID: 34087780
  149. Sanlorenzo, M.; Vujic, I.; Esteve-Puig, R.; Lai, K.; Vujic, M.; Lin, K.; Posch, C.; Dimon, M.; Moy, A.; Zekhtser, M.; Johnston, K.; Gho, D.; Ho, W.; Gajjala, A.; Oses Prieto, J.; Burlingame, A.; Daud, A.; Rappersberger, K.; Ortiz-Urda, S. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci. Rep., 2018, 8(1), 10902. doi: 10.1038/s41598-018-27643-3 PMID: 30026510
  150. Wu, K.; Wang, Q.; Liu, Y.L.; Xiang, Z.; Wang, Q.Q.; Yin, L.; Liu, S.L. LncRNA POU3F3 contributes to dacarbazine resistance of human melanoma through the MiR-650/MGMT axis. Front. Oncol., 2021, 11, 643613. doi: 10.3389/fonc.2021.643613 PMID: 33816296
  151. Long, J.; Pi, X. lncRNA-MEG3 suppresses the proliferation and invasion of melanoma by regulating CYLD expression mediated by sponging miR-499-5p. BioMed Res. Int., 2018, 2018, 1-15. doi: 10.1155/2018/2086564 PMID: 29808164
  152. Pan, B.; Lin, X.; Zhang, L.; Hong, W.; Zhang, Y. Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance. Melanoma Res., 2019, 29(3), 254-262. doi: 10.1097/CMR.0000000000000560 PMID: 30640294
  153. An, L.; Huang, J.; Han, X.; Wang, J. Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axis. Anticancer Drugs, 2020, 31(5), 473-482. doi: 10.1097/CAD.0000000000000888 PMID: 32265386
  154. Wu, L.; Li, K.; Lin, W.; Liu, J.; Qi, Q.; Shen, G.; Chen, W.; He, W. Long noncoding RNA LINC01291 promotes the aggressive properties of melanoma by functioning as a competing endogenous RNA for microRNA-625-5p and subsequently increasing IGF-1R expression. Cancer Gene Ther., 2022, 29(3-4), 341-357. doi: 10.1038/s41417-021-00313-9 PMID: 33674778
  155. Melixetian, M.; Bossi, D.; Mihailovich, M.; Punzi, S.; Barozzi, I.; Marocchi, F.; Cuomo, A.; Bonaldi, T.; Testa, G.; Marine, J.C.; Leucci, E.; Minucci, S.; Pelicci, P.G.; Lanfrancone, L. Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation. EMBO Rep., 2021, 22(3), e50852. doi: 10.15252/embr.202050852 PMID: 33586907
  156. Caporali, S.; Amaro, A.; Levati, L.; Alvino, E.; Lacal, P.M.; Mastroeni, S.; Ruffini, F.; Bonmassar, L.; Antonini Cappellini, G.C.; Felli, N.; Carè, A.; Pfeffer, U.; D’Atri, S. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. J. Exp. Clin. Cancer Res., 2019, 38(1), 272. doi: 10.1186/s13046-019-1238-4 PMID: 31227006
  157. Zheng, Y.; Sun, Y.; Liu, Y.; Zhang, X.; Li, F.; Li, L.; Wang, J. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway. Biochem. Biophys. Res. Commun., 2018, 503(4), 2451-2458. doi: 10.1016/j.bbrc.2018.06.175 PMID: 29969627
  158. Koetz-Ploch, L.; Hanniford, D.; Dolgalev, I.; Sokolova, E.; Zhong, J.; Díaz-Martínez, M.; Bernstein, E.; Darvishian, F.; Flaherty, K.T.; Chapman, P.B.; Tawbi, H.; Hernando, E. Micro RNA -125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res., 2017, 30(3), 328-338. doi: 10.1111/pcmr.12578 PMID: 28140520
  159. Díaz-Martínez, M.; Benito-Jardón, L.; Teixidó, J. New insights in melanoma resistance to BRAF inhibitors: A role for microRNAs. Oncotarget, 2018, 9(83), 35374-35375. doi: 10.18632/oncotarget.26244 PMID: 30459929
  160. Huber, V.; Vallacchi, V.; Fleming, V.; Hu, X.; Cova, A.; Dugo, M.; Shahaj, E.; Sulsenti, R.; Vergani, E.; Filipazzi, P.; De Laurentiis, A.; Lalli, L.; Di Guardo, L.; Patuzzo, R.; Vergani, B.; Casiraghi, E.; Cossa, M.; Gualeni, A.; Bollati, V.; Arienti, F.; De Braud, F.; Mariani, L.; Villa, A.; Altevogt, P.; Umansky, V.; Rodolfo, M.; Rivoltini, L. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest., 2018, 128(12), 5505-5516. doi: 10.1172/JCI98060 PMID: 30260323
  161. Gao, M.; Li, C.; Xiao, H.; Dong, H.; Jiang, S.; Fu, Y.; Gong, L. hsa_circ_0007841: A novel potential biomarker and drug resistance for multiple myeloma. Front. Oncol., 2019, 9, 1261. doi: 10.3389/fonc.2019.01261 PMID: 31803627
  162. Hanniford, D.; Ulloa-Morales, A.; Karz, A.; Berzoti-Coelho, M.G.; Moubarak, R.S.; Sánchez-Sendra, B.; Kloetgen, A.; Davalos, V.; Imig, J.; Wu, P.; Vasudevaraja, V.; Argibay, D.; Lilja, K.; Tabaglio, T.; Monteagudo, C.; Guccione, E.; Tsirigos, A.; Osman, I.; Aifantis, I.; Hernando, E. Epigenetic silencing of CDR1as drives iGF2BP3-mediated melanoma invasion and metastasis. Cancer Cell, 2020, 37(1), 55-70.e15. doi: 10.1016/j.ccell.2019.12.007 PMID: 31935372
  163. Zhou, X.; Yan, T.; Huang, C.; Xu, Z.; Wang, L.; Jiang, E.; Wang, H.; Chen, Y.; Liu, K.; Shao, Z.; Shang, Z. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J. Exp. Clin. Cancer Res., 2018, 37(1), 242. doi: 10.1186/s13046-018-0911-3 PMID: 30285793
  164. Bae, I.S.; Kim, S.H. Milk exosome-derived MicroRNA-2478 suppresses melanogenesis through the Akt-GSK3β pathway. Cells, 2021, 10(11), 2848. doi: 10.3390/cells10112848 PMID: 34831071
  165. Luan, W.; Ding, Y.; Xi, H.; Ruan, H.; Lu, F.; Ma, S.; Wang, J. Exosomal miR-106b-5p derived from melanoma cell promotes primary melanocytes epithelial-mesenchymal transition through targeting EphA4. J. Exp. Clin. Cancer Res., 2021, 40(1), 107. doi: 10.1186/s13046-021-01906-w PMID: 33741023
  166. Chen, Y.; Fang, Y.; Li, L.; Luo, H.; Cao, T.; Tu, B. Exosomal miR-22-3p from Mesenchymal Stem Cells Inhibits the Epithelial-Mesenchymal Transition (EMT) of melanoma cells by regulating LGALS1. Front. Biosci.-Landmark, 2022, 27(9), 275. doi: 10.31083/j.fbl2709275 PMID: 36224027
  167. Zeng, B.; Chen, Y.; Chen, H.; Zhao, Q.; Sun, Z.; Liu, D.; Li, X.; Zhang, Y.; Wang, J.; Xing, H.R. Exosomal miR-211-5p regulates glucose metabolism, pyroptosis, and immune microenvironment of melanoma through GNA15. Pharmacol. Res., 2023, 188, 106660. doi: 10.1016/j.phrs.2023.106660 PMID: 36642112
  168. Liu, D.; Li, X.; Zeng, B.; Zhao, Q.; Chen, H.; Zhang, Y.; Chen, Y.; Wang, J.; Xing, H.R. Exosomal microRNA-4535 of melanoma stem cells promotes metastasis by inhibiting autophagy pathway. Stem Cell Rev. Rep., 2023, 19(1), 155-169. doi: 10.1007/s12015-022-10358-4 PMID: 35296991
  169. Byrnes, C.C.; Jia, W.; Alshamrani, A.A.; Kuppa, S.S.; Murph, M.M. miR-122-5p expression and secretion in melanoma cells is amplified by the lpar3 sh3–binding domain to regulate Wnt1. Mol. Cancer Res., 2019, 17(1), 299-309. doi: 10.1158/1541-7786.MCR-18-0460 PMID: 30266753
  170. Li, J.; Chen, J.; Wang, S.; Li, P.; Zheng, C.; Zhou, X.; Tao, Y.; Chen, X.; Sun, L.; Wang, A.; Cao, K.; Tang, S.; Zhou, J. Blockage of transferred exosome-shuttled miR-494 inhibits melanoma growth and metastasis. J. Cell. Physiol., 2019, 234(9), 15763-15774. doi: 10.1002/jcp.28234 PMID: 30723916
  171. Chen, H.; Zeng, B.; Li, X.; Zhao, Q.; Liu, D.; Chen, Y.; Zhang, Y.; Wang, J.; Xing, H.R. High-metastatic melanoma cells promote the metastatic capability of low-metastatic melanoma cells via exosomal transfer of miR-411-5p. Front. Oncol., 2022, 12, 895164. doi: 10.3389/fonc.2022.895164 PMID: 35669425
  172. Zhao, Q.; Chen, H.; Li, X.; Zeng, B.; Sun, Z.; Liu, D.; Chen, Y.; Zhang, Y.; Rosie Xing, H.; Wang, J. Low-metastatic melanoma cells acquire enhanced metastatic capability via exosomal transfer of miR-199a-1-5p from highly metastatic melanoma cells. Cell Death Discov., 2022, 8(1), 188. doi: 10.1038/s41420-022-00993-8 PMID: 35397647
  173. Wang, X.; Cui, Z.; Zeng, B.; Qiong, Z.; Long, Z. Human mesenchymal stem cell derived exosomes inhibit the survival of human melanoma cells through modulating miR-138-5p/SOX4 pathway. Cancer Biomark., 2022, 34(4), 533-543. doi: 10.3233/CBM-210409 PMID: 35275523
  174. Hu, T.; Hu, J. Melanoma-derived exosomes induce reprogramming fibroblasts into cancer-associated fibroblasts via Gm26809 delivery. Cell Cycle, 2019, 18(22), 3085-3094. doi: 10.1080/15384101.2019.1669380 PMID: 31544590
  175. Wang, X.; Cheng, Q. Suppression of exosomal hsa_circ_0001005 eliminates the Vemurafenib resistance of melanoma. J. Cancer Res. Clin. Oncol., 2023, 149(9), 5921-5936. doi: 10.1007/s00432-022-04434-y PMID: 36598578
  176. Wei, C.Y.; Zhu, M.X.; Lu, N.H.; Liu, J.Q.; Yang, Y.W.; Zhang, Y.; Shi, Y.D.; Feng, Z.H.; Li, J.X.; Qi, F.Z.; Gu, J.Y. Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma. Mol. Cancer, 2020, 19(1), 84. doi: 10.1186/s12943-020-01191-9 PMID: 32381016
  177. Alegre, E.; Sanmamed, M.F.; Rodriguez, C.; Carranza, O.; Martín-Algarra, S.; González, Á. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch. Pathol. Lab. Med., 2014, 138(6), 828-832. doi: 10.5858/arpa.2013-0134-OA PMID: 24878024
  178. Zhong, D.; Wu, C.; Xu, D.; Bai, J.; Wang, Q.; Zeng, X. Plasma-Derived Exosomal hsa-miR-4488 and hsa-miR-1228-5p: Novel biomarkers for dermatomyositis-associated interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody-positive subset. BioMed Res. Int., 2021, 2021, 1-16. doi: 10.1155/2021/6676107 PMID: 34368354
  179. Guo, Y.; Zhang, X.; Wang, L.; Li, M.; Shen, M.; Zhou, Z.; Zhu, S.; Li, K.; Fang, Z.; Yan, B.; Zhao, S.; Su, J.; Chen, X.; Peng, C. The plasma exosomal miR-1180-3p serves as a novel potential diagnostic marker for cutaneous melanoma. Cancer Cell Int., 2021, 21(1), 487. doi: 10.1186/s12935-021-02164-8 PMID: 34544412
  180. Dejima, H.; Iinuma, H.; Kanaoka, R.; Matsutani, N.; Kawamura, M. Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol. Lett., 2017, 13(3), 1256-1263. doi: 10.3892/ol.2017.5569 PMID: 28454243
  181. Tamiya, H.; Mitani, A.; Saito, A.; Ishimori, T.; Saito, M.; Isago, H.; Jo, T.; Yamauchi, Y.; Tanaka, G.; Nagase, T. Exosomal MicroRNA expression profiling in patients with lung adenocarcinoma-associated malignant pleural effusion. Anticancer Res., 2018, 38(12), 6707-6714. doi: 10.21873/anticanres.13039 PMID: 30504380
  182. Wu, H.; Zhou, J.; Mei, S.; Wu, D.; Mu, Z.; Chen, B.; Xie, Y.; Ye, Y.; Liu, J. Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J. Cell. Mol. Med., 2017, 21(6), 1228-1236. doi: 10.1111/jcmm.13056 PMID: 28026121
  183. Aushev, V.N.; Zborovskaya, I.B.; Laktionov, K.K.; Girard, N.; Cros, M.P.; Herceg, Z.; Krutovskikh, V. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One, 2013, 8(10), e78649. doi: 10.1371/journal.pone.0078649 PMID: 24130905
  184. Zhou, W.; Fong, M.Y.; Min, Y.; Somlo, G.; Liu, L.; Palomares, M.R.; Yu, Y.; Chow, A.; O’Connor, S.T.F.; Chin, A.R.; Yen, Y.; Wang, Y.; Marcusson, E.G.; Chu, P.; Wu, J.; Wu, X.; Li, A.X.; Li, Z.; Gao, H.; Ren, X.; Boldin, M.P.; Lin, P.C.; Wang, S.E. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell, 2014, 25(4), 501-515. doi: 10.1016/j.ccr.2014.03.007 PMID: 24735924
  185. Eichelser, C.; Stückrath, I.; Müller, V.; Milde-Langosch, K.; Wikman, H.; Pantel, K.; Schwarzenbach, H. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget, 2014, 5(20), 9650-9663. doi: 10.18632/oncotarget.2520 PMID: 25333260
  186. Bryant, R.J.; Pawlowski, T.; Catto, J.W.F.; Marsden, G.; Vessella, R.L.; Rhees, B.; Kuslich, C.; Visakorpi, T.; Hamdy, F.C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer, 2012, 106(4), 768-774. doi: 10.1038/bjc.2011.595 PMID: 22240788
  187. Liu, M.X.; Liao, J.; Xie, M.; Gao, Z.K.; Wang, X.H.; Zhang, Y.; Shang, M.H.; Yin, L.H.; Pu, Y.P.; Liu, R. miR-93-5p transferred by exosomes promotes the proliferation of esophageal cancer cells via intercellular communication by targeting PTEN. Biomed. Environ. Sci., 2018, 31(3), 171-185. PMID: 29673440
  188. Hornick, N.I.; Huan, J.; Doron, B.; Goloviznina, N.A.; Lapidus, J.; Chang, B.H.; Kurre, P. Serum exosome MicroRNA as a minimally-invasive early biomarker of AML. Sci. Rep., 2015, 5(1), 11295. doi: 10.1038/srep11295 PMID: 26067326
  189. Taylor, D.D.; Gercel-Taylor, C. RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol., 2008, 110(1), 13-21. doi: 10.1016/j.ygyno.2008.04.033 PMID: 18589210
  190. Akers, J.C.; Ramakrishnan, V.; Kim, R.; Skog, J.; Nakano, I.; Pingle, S.; Kalinina, J.; Hua, W.; Kesari, S.; Mao, Y.; Breakefield, X.O.; Hochberg, F.H.; Van Meir, E.G.; Carter, B.S.; Chen, C.C. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): A platform for glioblastoma biomarker development. PLoS One, 2013, 8(10), e78115. doi: 10.1371/journal.pone.0078115 PMID: 24205116
  191. Shi, R.; Wang, P.Y.; Li, X.Y.; Chen, J.X.; Li, Y.; Zhang, X.Z.; Zhang, C.G.; Jiang, T.; Li, W.B.; Ding, W.; Cheng, S.J. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget, 2015, 6(29), 26971-26981. doi: 10.18632/oncotarget.4699 PMID: 26284486
  192. Zeng, A.; Wei, Z.; Yan, W.; Yin, J.; Huang, X.; Zhou, X.; Li, R.; Shen, F.; Wu, W.; Wang, X.; You, Y. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Cancer Lett., 2018, 436, 10-21. doi: 10.1016/j.canlet.2018.08.004 PMID: 30102952
  193. Manterola, L.; Guruceaga, E.; Pérez-Larraya, J.G.; González-Huarriz, M.; Jauregui, P.; Tejada, S.; Diez-Valle, R.; Segura, V.; Samprón, N.; Barrena, C.; Ruiz, I.; Agirre, A.; Ayuso, Á.; Rodríguez, J.; González, Á.; Xipell, E.; Matheu, A.; López de Munain, A.; Tuñón, T.; Zazpe, I.; García-Foncillas, J.; Paris, S.; Delattre, J.Y.; Alonso, M.M. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-oncol., 2014, 16(4), 520-527. doi: 10.1093/neuonc/not218 PMID: 24435880
  194. Yang, J.K.; Yang, J.P.; Tong, J.; Jing, S.Y.; Fan, B.; Wang, F.; Sun, G.Z.; Jiao, B.H. Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. J. Neurooncol., 2017, 131(2), 255-265. doi: 10.1007/s11060-016-2308-5 PMID: 27837435
  195. Lan, F.; Qing, Q.; Pan, Q.; Hu, M.; Yu, H.; Yue, X. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol., 2018, 41(1), 25-33. doi: 10.1007/s13402-017-0355-3 PMID: 29076027
  196. Cai, Q.; Zhu, A.; Gong, L. Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1. Bull. Cancer, 2018, 105(7-8), 643-651. doi: 10.1016/j.bulcan.2018.05.003 PMID: 29921422
  197. Santangelo, A.; Imbrucè, P.; Gardenghi, B.; Belli, L.; Agushi, R.; Tamanini, A.; Munari, S.; Bossi, A.M.; Scambi, I.; Benati, D.; Mariotti, R.; Di Gennaro, G.; Sbarbati, A.; Eccher, A.; Ricciardi, G.K.; Ciceri, E.M.; Sala, F.; Pinna, G.; Lippi, G.; Cabrini, G.; Dechecchi, M.C. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J. Neurooncol., 2018, 136(1), 51-62. doi: 10.1007/s11060-017-2639-x PMID: 29076001
  198. Liu, L.; Meng, T.; Yang, X.H.; Sayim, P.; Lei, C.; Jin, B.; Ge, L.; Wang, H.J. Prognostic and predictive value of long non-coding RNA GAS5 and mircoRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion. Cancer Biomark., 2018, 22(2), 283-299. doi: 10.3233/CBM-171011 PMID: 29630521
  199. Pan, L.; Liang, W.; Fu, M.; Huang, Z.; Li, X.; Zhang, W.; Zhang, P.; Qian, H.; Jiang, P.; Xu, W.; Zhang, X. Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J. Cancer Res. Clin. Oncol., 2017, 143(6), 991-1004. doi: 10.1007/s00432-017-2361-2 PMID: 28285404
  200. Li, Q.; Shao, Y.; Zhang, X.; Zheng, T.; Miao, M.; Qin, L.; Wang, B.; Ye, G.; Xiao, B.; Guo, J. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol., 2015, 36(3), 2007-2012. doi: 10.1007/s13277-014-2807-y PMID: 25391424

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers